Skip to main content

TAK-341-2001 Takeda Development Center Americas, Inc. / “A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Mul

NCT05526391

Takeda Development Center Americas, Inc. / “A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy”

Associated Conditions

Movement Disorders

Principal Investigator

Sponsor

Takeda Development Center Americas

Multiple System Atrophy: The goals of this study are to find out the following: How effective is TAK-341 in treating people with MSA.
Assess what TAK-341 does to the body (pharmacokinetics [PK]) and measure the amount of TAK-341 in blood and cerebrospinal fluid (CSF, the fluid that flows in and around the hollow spaces of the brain and spinal cord) in people with MSA. How safe is TAK-341? Are there any unwanted effects on your health that might be related to the use of TAK-341? Assess how your body’s defense (immune) system reacts to TAK-341.

This study is currently enrolling.